153
Views
3
CrossRef citations to date
0
Altmetric
Original Research

Twelve weeks of ombitasvir/paritaprevir/r and dasabuvir without ribavirin is effective and safe in the treatment of patients with HCV genotype 1b infection and compensated cirrhosis: results from a real-world cohort study

, ORCID Icon, , , , , & show all
Pages 235-241 | Received 24 Oct 2017, Accepted 03 Jan 2018, Published online: 11 Jan 2018

Keep up to date with the latest research on this topic with citation updates for this article.

Articles from other publishers (3)

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.